

Current level of influenza activity: Low

Influenza activity trend: Increasing

Confirmed influenza cases since 2022 week 40: 1149 (510 influenza A(H3N2), 287 influenza A(H1N1)pdm09, 318 influenza A(not subtyped) and 34 influenza B)

Key points – Wales


Influenza is beginning to circulate in Wales and confirmed cases of RSV remain at very high intensity levels.

During Week 47 (ending 27/11/2022) there were 184 cases of influenza (an increase from the previous week), with a further nine samples from previous weeks. This total now includes a number of samples from children who tested positive for flu that were previously excluded whilst their LAIV record was checked. COVID-19 cases continue to be detected in symptomatic patients in hospitals and in the community. RSV incidence in children under 5 years of age is currently at levels that would indicate very high levels of activity (compared to the 10 seasons leading up to 2020). Rhinovirus, RSV and adenovirus are the most commonly detected cause of non-COVID-19 Acute Respiratory Infection (ARI).

- The **Sentinel GP consultation rate for influenza-like illness (ILI)** in Wales during week 47, was 4.3 consultations per 100,000 practice population (Table 1). This is an increase compared to the previous week (3.2 consultations per 100,000) and remains below the baseline threshold for seasonal influenza activity (11.0 per 100,000 practice population) (Figure 1). Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic.
- The **Sentinel GP consultation rate for Acute Respiratory Infections (ARI)** was 261.7 per 100,000 practice population during Week 47, this is an increase compared to the previous week (221.2 per 100,000) (Table 2 and Figure 3). Weekly consultations for both Lower Respiratory Tract Infections and Upper Respiratory Tract Infections increased compared to the previous week.
- The percentage of calls to **NHS Direct Wales** which were 'influenza-related' (cold/flu, cough, fever, headache and sore throat) during Week 47 increased to 25.7% (Figure 9).
- During Week 47, 1,640 specimens received multiplex respiratory panel testing mainly from patients attending hospitals. These results do not include samples tested solely for SARS-CoV-2. There were 131 samples positive for influenza of which 38 were A(H1N1), 90 were A(H3N2), two were A(not typed), and one was influenza B. Overall influenza positivity was 8.0% across all age groups; 6.6% in those aged 18 years and over; and 10.6% in those aged under 18 years. In addition there were 280 RSV, 36 parainfluenza, 317 rhinovirus, 69 human metapneumovirus, 131 adenovirus, 42 enterovirus, 25 seasonal coronavirus and 203 SARS-CoV-2 positive samples in Week 47 (Figure 5). Additionally, 1,015 samples from patients were tested for influenza, RSV and SARS-CoV-2 only, many of these tests may be associated with screening activities rather than diagnostic testing for patients presenting with ARI symptoms. Of these 1,015 samples, 41 were positive for influenza A and three for influenza B, 47 were positive for RSV and 93 were positive for SARS-CoV-2 (Figure 6). 90 respiratory specimens were tested from patients in intensive care units (ICU) of which two were positive for influenza (one A(H3N2), one A(not subtyped)). (Figure 7). For the latest COVID-19/ SARS-CoV2 surveillance data please see the [PHW daily dashboard](#)
- There were 86 surveillance samples from patients with ILI symptoms collected by **sentinel GPs and community pharmacies** during Week 47. Of the 86 samples, nine samples tested positive for influenza (five A(H3N2), three A(H1N1) and one A(not subtyped)), nine for RSV, 24 for rhinovirus, five for adenovirus, two for parainfluenza, one for human metapneumovirus, two for enterovirus and seven for SARS-CoV-2 (as at 30/11/2022) (Figure 4).
- **Confirmed RSV case incidence in children aged under 5 has increased compared to the previous week and remains at very high intensity levels.** In week 47 there were 111.6 confirmed cases per 100,000 in this age group (Figure 7). The provisional MEM threshold in Wales which predicts the start of the annual RSV season in children younger than five years is 6.3 confirmed cases per 100,000.
- During Week 47, 17 **ARI outbreaks** were reported to the Public Health Wales Health Protection team, all of them were reported as COVID-19. All 17 of these **ARI outbreaks** were reported in residential care homes.
- According to [EuroMoMo](#) analysis, all-cause deaths in Wales were not significantly in excess during week 47.

Respiratory infection activity in Wales


Figure 1. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (as of 27/11/2022).



* The Moving Epidemic Method (MEM) threshold calculated for Wales ILI consultation rates is 11.1 per 100,000. MEM thresholds used in this chart are based on influenza from 2010-11 to 2018-19 seasons. Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic.

**Clinical consultations for ILI seasons are monitored from W40 to W40, the most recent data is presented in red.

Figure 2. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (week 48 1996 – week 47 2022).



* Reporting changed to Audit+ surveillance system

Table 1. Age-specific consultations (per 100,000) for ILI in Welsh sentinel practices, week 42 – week 47 2022 (as of 27/11/2022).

Age group	42	43	44	45	46	47
< 1	0.0	0.0	0.0	0.0	0.0	0.0
1 - 4	13.6	6.8	6.8	6.8	6.8	7.1
5 - 14	4.5	2.2	2.2	2.2	0.0	0.0
15 - 24	0.0	0.0	6.5	2.2	0.0	6.9
25 - 34	2.0	9.7	5.8	9.7	5.8	8.2
35 - 44	5.8	11.5	15.4	17.3	3.8	10.2
45 - 64	3.7	4.6	3.7	7.3	3.7	1.9
65 - 74	4.4	2.2	4.3	6.5	4.3	4.5
75+	2.3	2.3	9.0	2.2	2.2	0.0
Total	3.7	4.9	6.3	7.0	3.2	4.3

Table 2. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 42 – week 47 2022 (as of 27/11/2022).

Age group	42	43	44	45	46	47
< 1	1209.7	1330.9	1616.4	2022.4	1779	1981.5
1 - 4	1043.8	1076.2	1143.6	1006.1	1052.4	1361.7
5 - 14	302.7	333.63	230.65	302.4	304.5	433.31
15 - 24	146.7	180.24	206.08	177.95	175.8	214.71
25 - 34	179.4	170.05	171.9	170.12	208.66	217.04
35 - 44	176.5	207.52	178.53	185.99	157.15	172.48
45 - 64	155.0	162.98	162.08	134.66	140.12	156.67
65 - 74	107.0	164.55	175.33	149.38	149.4	172.27
75+	192.1	195.46	181.95	150.4	159.12	157.45
Total	214.6	235.4	227.9	217.9	221.2	261.7

Figure 3. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 1 – week 47 2022 (as of 27/11/2022).






Figure 4. Specimens submitted for virological testing by sentinel GPs as of 27/11/2022, by week of sample collection, week 47 2021 to week 47 2022.



* Tested negative for influenza, adenovirus, rhinovirus, RSV, parainfluenza, mycoplasma, human metapneumovirus, enterovirus, bocavirus and coronaviruses. Samples which test positive for more than on pathogen will appear more than once in the chart.

Figure 5. Specimens submitted for virological testing for hospital patients and non-sentinel GPs as of 27/11/2022 by week of sample collection, week 47 2021 to week 47 2022.



This chart summarises respiratory panel test data and does not include data for patients tested SOLELY for SARS-CoV2. Combined data for tests carried out in Public Health Wales Microbiology: Cardiff laboratory, provided by Public Health Wales Microbiology Cardiff Specialist Virology Centre. This chart summarises individual test results, patients who are positive for multiple infections within a given week will appear multiple times. Samples which test positive for more than on pathogen will appear more than once in the chart.

Figure 6. Specimens from hospital patients submitted for RSV, Influenza and SARS-CoV2 testing only, as of 27/11/2022 by week of sample collection, week 47 2021 to week 47 2022.






Figure 7. Specimens submitted for virological testing for ICU patients, by week of sample collection, week 47 2021 to Week 47 2022.



This chart summarises respiratory panel test data and does not include data for patients tested SOLELY for SARS-CoV2. Samples which test positive for more than one pathogen will appear more than once in the chart.


Figure 8. RSV incidence rate per 100,000 population aged under five years, week 30 2018 to Week 47 2022.



*RSV seasons are monitored from W30 to W29, the most recent data is presented in red

Calls to NHS Direct Wales

Figure 9. Influenza related calls to NHS Direct Wales¹ (as a percentage of total calls) from week 47 2018 - Week 47 2022 (as of 27/11/2022).



¹ Data supplied by Health Statistics and Analysis Unit, Welsh Government.

Flu related calls are the sum of calls recorded as 'cold/flu', 'cough', 'headache', 'fever' and 'sore throat'. Following changes to the NHS Direct calls system, including the start of the 111 pilot, there has been a change in the way in which denominator data are calculated for this chart, NHS Direct Wales now count the total number of nurse triaged calls (i.e. calls which could have symptom data recorded against them), note that 111 includes out-of-hours calls.

Influenza Vaccine Uptake in Wales

Table 3. Uptake of influenza immunisations in GP Practice patients in Wales 2022/23 (as of 22/11/2022).

Influenza immunisation uptake in the 2022/23 season	
People aged 65y and older	69.2%
People younger than 65y in a clinical risk group	35.2%
Children aged two & three years	30.9%
Children aged between four & ten years	55.5%
Children aged between 11 & 15 years	44.4%
Total NHS staff	33.7%
NHS staff with direct patient contact	33.9%

Uptake in other eligible groups will be available in the coming weeks.

The end of season report Influenza in Wales 2019/20 is available to download and contains a full breakdown of vaccination uptake amongst eligible groups.

Link to report: <https://phw.nhs.wales/topics/immunisation-and-vaccines/flu vaccine/annual-influenza-surveillance-and-influenza-vaccination-uptake-reports/>

Influenza activity – UK and international summary

- As of week 46, community and syndromic influenza indicators remained below baseline levels in the UK. GP ILI consultations decreased in Northern Ireland to 3.5 per 100,000, and in Scotland to 4.6 per 100,000 - well below the baseline intensity threshold. The weekly ILI GP consultation rate in England reported through the RCGP system increased to 5.3 per 100,000, below the MEM threshold for baseline activity (12.2 per 100,000).
- During week 46, 361 samples tested positive for influenza in England (including 15 A(H1N1)pdm09, 78 A(H3N2), 268 A(not subtyped) and 23 influenza B). Overall influenza positivity remained fairly stable at 8.2%. UK summary data are available from the [UKHSA Influenza and COVID-19 Surveillance Report](#).
- The WHO and the European Centre for Disease Prevention and Control (ECDC) reported in its weekly influenza update, that during week 46, 18 countries reported baseline-intensity, 18 reported low-intensity, one reported medium-intensity (Romania) and two reported high-intensity (Malta and Kazakhstan). Eight out of 39 reporting countries reported no influenza activity across the region, 19 reported sporadic spread, three reported local spread (Malta, Austria and United Kingdom (Northern Ireland)), seven reported regional spread (Albania, Finland, France, Kazakhstan, Republic of Moldova, Russian Federation and Ukraine), and two reported widespread activity (Germany and Scotland). During week 47, 331 of 2,777 (12%) samples from patients presenting to all sentinel primary care centres with ILI or ARI symptoms were tested positive for influenza. This is a decrease from the previous week but remains above the threshold for epidemic activity (10%). Of sentinel specimens that tested positive for influenza for the season to date, 87% were influenza A (85% H3, 15% A(H1N1)pdm09) and 13% were influenza B. **Source:** Flu News Europe: <http://www.flunewseurope.org/>
- The WHO reported on 28/11/2022, based on data up to 13/11/2022, that globally, influenza activity has increased, with influenza A(H3N3) predominating.
- In the temperate zones of the southern hemisphere, overall influenza has further decreased with the exemption of Argentina and Chile. Specifically, A(H3N2) predominated in Chile, and influenza B followed by A(H1N1)pdm09 in Argentina.
- In tropical South America, influenza detections remained low with A(H3N2) viruses predominating. In the Caribbean and Central American countries, influenza detections of predominantly A(H3N2) virus increased, mainly in Mexico. Puerto Rico, Guatemala, Panama and Nicaragua also reported slightly increased influenza activity.
- In Western Africa, influenza activity remained decreased, although influenza B/Victoria followed by A(H3N2) detections were sporadically reported. In Middle Africa, sporadic detections of A(H3N2) were reported. In Eastern Africa, influenza A and B detections decreased.
- In Southern Asia, influenza detections of predominately A(H3N2) viruses increased steeply mainly due to an increase in activity reported in Iran. Influenza A(H3N2) predominated, though detections of A(H1N1)pdm09 and influenza B viruses were also reported. In South-East Asia, influenza activity decreased. In East Asia, influenza activity of predominantly influenza A(H3N2) continue to be reported but remained stable at intermediate levels overall. In Western Asia, influenza detections remained elevated mainly in some countries of the Arab Peninsula.
- In Central Asia, specifically in Kazakhstan, high influenza activity was reported of predominantly influenza B viruses. Influenza like illnesses and severe acute respiratory infections activity has also increased.
Source: WHO influenza update: <https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-updates/current-influenza-update>
- Based on FluNet reporting (as of 29/11/2022), during the time period from 31/10/2022 – 13/10/2022, National Influenza Centres and other national influenza laboratories from 125 countries, areas or territories reported influenza surveillance data. The WHO Global Influenza Surveillance and Response System laboratories tested more than 465,365 specimens during that time period, of which 56,551 were positive for influenza viruses. 53,829 (95.2%) of those positive for influenza were typed as influenza A (of the subtyped influenza A viruses, 2,024 (16.3%) were influenza A(H1N1)pdm09 and 10,356 (83.7%) were influenza A(H3N2)) and 2,722 (4.8%) influenza B (of the 550 characterised influenza B viruses, all belonged to the B-Victoria lineage). **Source:** FluNet: <https://www.who.int/tools/flunet>

Update on influenza activity in North America

- The USA Centers for Disease Control and Prevention (CDC) report that there have been early increases in seasonal influenza activity in the United States during week 46 (ending 19/11/2022). Nationally, 21,796 (18.2%) out of 119,615 specimens have tested positive for influenza in week 46 in clinical laboratories nationwide, of these positives 21,677 (99.5%) were influenza A and 119 (0.5%) were influenza B. Further characterisation has been carried out on 9,673 specimens by public health laboratories, and 1,423 samples tested positive for influenza;

206 influenza A(H1N1)pdm09 (24.2%), 646 influenza A(H3N2) (75.8%), 566 influenza A(not subtyped) and five influenza B.

Source: CDC Weekly US Influenza Surveillance Report: <http://www.cdc.gov/flu/weekly/>

- The Public Health Agency of Canada reported that during week 46, influenza activity has continued to increase along with most surveillance indicators and all are above expected levels. During week 46, 5,891 influenza detections were reported: 5,876 influenza A (predominantly A(H3N2) at 97%), and 15 influenza B. The percentage of ILI visits rose to 2.6% in week 45.

Source: Public Health Agency of Canada: <https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html>

Respiratory syncytial virus (RSV) in North America

- The USA CDC reported an out of season increase in RSV activity, beginning in February 2022. This followed out-of-season activity also reported during 2021. RSV positivity rate and detections both decreased in the week beginning 19/11/2022.

Source: CDC RSV national trends: <https://www.cdc.gov/surveillance/nrvss/rsv/natl-trend.html>

COVID-19 – UK and international summary

- As of 23/11/2022, the new positive PCR episodes for the most recent 7-day reporting period was 9 per 100,000 population in Wales. There were 12 suspected COVID-19 deaths with a date of death in the most recent 7-day reporting period, reported to Public Health Wales. There were 40 COVID-19 death registrations in the last reporting period provided by ONS. Latest COVID-19 data from Public Health Wales is available from: <https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/>
- The latest UKHSA COVID-19 data summary is available from: <https://coronavirus.data.gov.uk/>
- WHO situation updates on COVID-19 are available from: <https://covid19.who.int/>

Middle East respiratory syndrome coronavirus (MERS-CoV) – latest update from WHO and ECDC

- On 16/11/22 WHO reported four laboratory-confirmed cases of locally acquired Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia from 29/12/2021 to 31/10/2022. This follows on from one laboratory-confirmed case in Oman reported on 28/04/2022, and two (including 1 death) reported from Qatar between 22/03/2022 to 03/04/2022. Since the beginning of 2022 and as of 22/11/2022 there have been six reported cases of MERS-CoV, with an additional case reported from 29/12/2022. As of 16/11/2022, 2,600 laboratory confirmed cases of human infection with MERS-CoV, including 935 associated deaths, from across the globe have officially been reported to WHO since 2012.

Source: WHO Global Alert and Response website: <https://www.who.int/emergencies/disease-outbreak-news>

- The majority of the MERS cases continue to be reported from Middle Eastern countries within the Arabian Peninsula, and specifically from Saudi Arabia. Rapid risk assessments of the situation from ECDC, which contain epidemiological updates and advice for travellers and healthcare workers, are available from: <https://ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus>
- Further updates and advice for healthcare workers and travellers are available from WHO: <http://www.who.int/emergencies/mers-cov/en/> and from NaTHNaC: <https://travelhealthpro.org.uk/news/237/mers-cov-update-travelhealthpro-country-pages>

Human infection with avian influenza A(H7N9), China

- The latest WHO Influenza at Human-Animal Interface summary (31/08/2022 – 05/10/2022) reports that there have been no publicly available reports from China or other countries on influenza A(H7N9) in recent months. Since February 2013, a total of 1,568 laboratory-confirmed cases of human infection with avian influenza A(H7N9), including at least 616 deaths, have been reported to the global influenza programme:

<https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary>

The risk of international spread of avian influenza A(H7N9) is considered to be low at present. However, it is important that clinicians are aware of the possibility of human infection with animal influenza, in persons presenting with severe acute respiratory disease, while travelling or soon after returning from an area where avian influenza is a concern. WHO Global Alert & Response updates: <https://www.who.int/emergencies/disease-outbreak-news>

Links:

Public Health Wales influenza surveillance webpage:

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=25480>

Public Health Wales COVID-19 data dashboard:

<https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/>

GP Sentinel Surveillance of Infections Scheme:

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=27918>

NICE influenza antiviral usage guidance:

<http://www.nice.org.uk/Guidance/TA158>

England influenza and COVID-19 surveillance:

<https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2022-to-2023-season>

Scotland seasonal respiratory surveillance:

<https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/weekly-national-seasonal-respiratory-report/>

Northern Ireland influenza surveillance:

<https://www.publichealth.hscni.net/directorate-public-health/health-protection/seasonal-influenza>

European Centre for Communicable Disease:

<http://ecdc.europa.eu/>

European influenza information:

<http://flunewseurope.org/>

Advice on influenza immunisation

<https://phw.nhs.wales/topics/immunisation-and-vaccines/fluvaccine/>

Advice on influenza immunisation (for intranet users)

[Influenza \(sharepoint.com\)](#)

For further information on this report, please email Public Health Wales using:

surveillance.requests@wales.nhs.uk